Interreg SKiN-HUID: Progress in Personalised Medicine (CANCELLED)Event date: May 16, 201911:00u
End date: May 16, 2019
11.00h - 17.00h
Progress in Personalised Medicine ‘Developing a novel biopharmaceutical, from bench to production’
SKiN-HUID develops a novel treatment of skin cancer that combines administration of a biopharmaceutical medicine targeting cancer cells and application of electrical and hyperthermal stimulation of the cancer that enhances the efficacy of the biopharmaceutical medicine.
Within SKiN-HUID the consortium aims to overcome the major hurdle of bringing a novel biopharmaceutical product to the clinic: the GMP-production of clinical grade biopharmaceutical medicine for the first phase of clinical studies. Basic Pharma set up a novel pilot plant for the GMP-production of biopharmaceutical medicines. This facility forms an essential part of the value chain linking preclinical and clinical evaluation of the efficacy of biopharmaceutical medicines.